bionumerik
1 known investors
BioNumerik Pharmaceuticals is a San Antonio, Texas-based pharmaceutical company that filed for a Nasdaq IPO in 2004.
Also known as BioNumerik Pharmaceuticals · BioNumerik Pharmaceuticals, Inc.
Investors · 1
Company profile
researched Aug 2026BioNumerik Pharmaceuticals, Inc. is a pharmaceutical company incorporated in Texas and headquartered at 8122 Datapoint Drive, Suite 1250, San Antonio, Texas. The company is classified under Standard Industrial Classification code 2834 (pharmaceutical preparations) in its filings with the U.S. Securities and Exchange Commission.
In June 2004 the company filed a Form S-1 registration statement covering an initial public offering of common stock with a par value of $0.01 and a proposed maximum aggregate offering price of $86.25 million. The company applied to have the common stock quoted on the Nasdaq National Market under the ticker symbol "BNPI". Prior to the 2004 filing, the company had filed a separate Form S-1 in March 2001 for $50 million of securities; those securities went unsold and the registration was withdrawn in November 2001.
Latest developments
The 2004 registration statement was filed on a preliminary basis, stating that the prospectus was not complete and that securities could not be sold until the registration statement became effective. UBS Investment Bank, Needham & Company, Leerink Swann & Company and Punk, Ziegel & Company were named as underwriters for the proposed offering.
▸Full profile — geography, history
Geography
Principal executive offices are located at 8122 Datapoint Drive, Suite 1250, San Antonio, Texas 78229. The company is incorporated in the State of Texas.
History
The company registered securities with the SEC on two occasions: a Form S-1 filed on March 2, 2001 covering $50,000,000 of securities, which was withdrawn on November 16, 2001 with all securities unsold, and a subsequent Form S-1 filed on June 8, 2004 covering up to $86,250,000 of common stock. At the time of the 2004 filing, no public market existed for the company's common stock.
Compiled by commissioned research from 2 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 2
launches, deals, and filingsBioNumerik Pharmaceuticals filed a Form S-1 with the U.S. Securities and Exchange Commission on June 8, 2004, registering up to $86,250,000 of common stock for an initial public offering, with an application to quote the shares on the Nasdaq National Market under the symbol 'BNPI'. Underwriters listed were UBS Investment Bank, Needham & Company, Leerink Swann & Company and Punk, Ziegel & Company.
$86.3M source ↗
A prior Form S-1 (file no. 333-56504) filed on March 2, 2001 registered $50,000,000 of securities; all securities were unsold and were withdrawn from registration on November 16, 2001.
$50M source ↗
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 2
primary sources listed
- sv1sec.gov · web
2 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does bionumerik do?
- BioNumerik Pharmaceuticals is a San Antonio, Texas-based pharmaceutical company that filed for a Nasdaq IPO in 2004.
- Who are bionumerik's investors?
- bionumerik's investors include Access Venture Partners.